<p>, /PRNewswire/ --</p>
<p>原因：罗森律师事务所是一家全球投资者权益律师事务所，提醒在 2024 年 3 月 10 日至 2025 年 9 月 29 日期间（包括这两个日期）购买 MoonLake Immunotherapeutics（纳斯达克代码：MLTX）普通股的投资者，注意 2025 年 12 月 15 日的主要原告截止日期。</p>
<p>那么，如何处理：如果您在该期间购买了 MoonLake 普通股，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
<p>接下来该做什么：要加入 MoonLake 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=45681 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。如果您希望担任主要原告，您必须在 2025 年 12 月 15 日之前向法院提出申请。主要原告是代表其他集体成员在诉讼中行事的代表方。</p>
<p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色上有成功记录的合格律师事务所。通常，发布通知的事务所没有可比的经验、资源或任何有意义的同行认可。这些事务所中的许多并不真正进行证券集体诉讼，而只是作为中介，转介客户或与实际进行案件诉讼的律师事务所合作。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾获得针对中国公司的最大证券集体诉讼和解。该事务所于 2017 年被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年均排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元。在 2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
<p>案件详情：根据投诉，在整个集体诉讼期间，被告做出了虚假和/或误导性的陈述，并未披露有关纳米抗体和单克隆抗体之间区别的重大事实，包括：（1）SLK 和 BIMZELX 共享相同的分子靶点（炎症细胞因子 IL-17A 和 IL-17F）；（2）SLK 独特的纳米抗体结构不会比 BIMZELX 的传统单克隆结构提供更优越的临床益处；（3）SLK 独特的纳米抗体结构所声称的组织渗透不会转化为临床疗效；（4）基于上述原因，被告对 SLK 声称优于单克隆抗体的积极陈述缺乏合理依据。当真实情况进入市场时，诉讼声称投资者遭受了损失。</p>
<p>要加入 MoonLake Immunotherapeutics 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=45681 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
<p>尚未认证集体。直到集体被认证，您不会被律师代表，除非您聘请一位。您可以选择自己喜欢的律师。您也可以选择保持缺席集体成员身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任主要原告。</p>
<p>关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/.</p>
<p>律师广告。以往的结果并不保证类似的结果。</p>
<p>联系信息：</p>
<p>Laurence Rosen, Esq.</p>
<p>Phillip Kim, Esq.</p>
<p>罗森律师事务所</p>
<p>275 Madison Avenue, 40th Floor</p>
<p>纽约， NY 10016</p>
<p>电话: (212) 686-1060</p>
<p>免费电话: (866) 767-3653</p>
<p>传真: (212) 202-3827</p>
<p>[email protected]</p>
<p>www.rosenlegal.com</p>
<p>来源：罗森律师事务所</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIyJk5ld3NJdGVtSWQ9REMzMTQyMSZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjIxMzIzUFJfTkVXU19VU1BSX19fX19EQzMxNDIx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIyJk5ld3NJdGVtSWQ9REMzMTQyMSZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjIxMzIzUFJfTkVXU19VU1BSX19fX19EQzMxNDIx"/></p>

MLTX

<p>罗森律师事务所提醒在 2024 年 3 月 10 日至 2025 年 9 月 29 日期间购买了 MoonLake Immunotherapeutics（纳斯达克代码：MLTX）股票的投资者，注意 2025 年 12 月 15 日的主要原告截止日期，涉及一起证券欺诈诉讼。投资者可能有权获得赔偿，无需自掏腰包。该诉讼指控关于 SLK 的纳米抗体结构存在虚假/误导性陈述。如需更多信息，请联系罗森律师事务所</p>

<p>, /PRNewswire/ --</p>
<div class="lb-trans"><p>, /PRNewswire/ --</p>
</div><p>Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the &#34;Class Period&#34;), of the important December 15, 2025 lead plaintiff deadline.</p>
<div class="lb-trans"><p>原因：罗森律师事务所是一家全球投资者权益律师事务所，提醒在 2024 年 3 月 10 日至 2025 年 9 月 29 日期间（包括这两个日期）购买 MoonLake Immunotherapeutics（纳斯达克代码：MLTX）普通股的投资者，注意 2025 年 12 月 15 日的主要原告截止日期。</p>
</div><p>So what: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p>
<div class="lb-trans"><p>那么，如何处理：如果您在该期间购买了 MoonLake 普通股，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
</div><p>What to do next: To join the MoonLake class action, go to https://rosenlegal.com/submit-form/?case_id=45681 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p>
<div class="lb-trans"><p>接下来该做什么：要加入 MoonLake 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=45681 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。如果您希望担任主要原告，您必须在 2025 年 12 月 15 日之前向法院提出申请。主要原告是代表其他集体成员在诉讼中行事的代表方。</p>
</div><p>Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.</p>
<div class="lb-trans"><p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色上有成功记录的合格律师事务所。通常，发布通知的事务所没有可比的经验、资源或任何有意义的同行认可。这些事务所中的许多并不真正进行证券集体诉讼，而只是作为中介，转介客户或与实际进行案件诉讼的律师事务所合作。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾获得针对中国公司的最大证券集体诉讼和解。该事务所于 2017 年被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年均排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元。在 2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
</div><p>Details of the case: According to the complaint, throughout the Class Period, defendants made false and/or misleading statements, as well as failed to disclose material facts, regarding the distinction between the Nanobodies and monoclonal antibodies, including that: (1) SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK's distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK's distinct Nanobody structure supposed tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK's purported superiority to monoclonal antibodies. When the true details entered the market, the lawsuit claims that investors suffered damages.</p>
<div class="lb-trans"><p>案件详情：根据投诉，在整个集体诉讼期间，被告做出了虚假和/或误导性的陈述，并未披露有关纳米抗体和单克隆抗体之间区别的重大事实，包括：（1）SLK 和 BIMZELX 共享相同的分子靶点（炎症细胞因子 IL-17A 和 IL-17F）；（2）SLK 独特的纳米抗体结构不会比 BIMZELX 的传统单克隆结构提供更优越的临床益处；（3）SLK 独特的纳米抗体结构所声称的组织渗透不会转化为临床疗效；（4）基于上述原因，被告对 SLK 声称优于单克隆抗体的积极陈述缺乏合理依据。当真实情况进入市场时，诉讼声称投资者遭受了损失。</p>
</div><p>To join the MoonLake Immunotherapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45681 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.</p>
<div class="lb-trans"><p>要加入 MoonLake Immunotherapeutics 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=45681 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
</div><p>No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p>
<div class="lb-trans"><p>尚未认证集体。直到集体被认证，您不会被律师代表，除非您聘请一位。您可以选择自己喜欢的律师。您也可以选择保持缺席集体成员身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任主要原告。</p>
</div><p>Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.</p>
<div class="lb-trans"><p>关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/.</p>
</div><p>Attorney Advertising. Prior results do not guarantee a similar outcome.</p>
<div class="lb-trans"><p>律师广告。以往的结果并不保证类似的结果。</p>
</div><p>Contact Information:</p>
<div class="lb-trans"><p>联系信息：</p>
</div><p>Laurence Rosen, Esq.</p>
<div class="lb-trans"><p>Laurence Rosen, Esq.</p>
</div><p>Phillip Kim, Esq.</p>
<div class="lb-trans"><p>Phillip Kim, Esq.</p>
</div><p>The Rosen Law Firm, P.A.</p>
<div class="lb-trans"><p>罗森律师事务所</p>
</div><p>275 Madison Avenue, 40th Floor</p>
<div class="lb-trans"><p>275 Madison Avenue, 40th Floor</p>
</div><p>New York, NY 10016</p>
<div class="lb-trans"><p>纽约， NY 10016</p>
</div><p>Tel: (212) 686-1060</p>
<div class="lb-trans"><p>电话: (212) 686-1060</p>
</div><p>Toll Free: (866) 767-3653</p>
<div class="lb-trans"><p>免费电话: (866) 767-3653</p>
</div><p>Fax: (212) 202-3827</p>
<div class="lb-trans"><p>传真: (212) 202-3827</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.rosenlegal.com</p>
<div class="lb-trans"><p>www.rosenlegal.com</p>
</div><p>SOURCE THE ROSEN LAW FIRM, P. A.</p>
<div class="lb-trans"><p>来源：罗森律师事务所</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIyJk5ld3NJdGVtSWQ9REMzMTQyMSZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjIxMzIzUFJfTkVXU19VU1BSX19fX19EQzMxNDIx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC31421&amp;Transmission_Id=202511221323PR_NEWS_USPR_____DC31421&amp;DateId=20251122"/></p>

MLTX 投资者有机会主导 MoonLake Immunotherapeutics 的证券欺诈诉讼